TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide

Blockhead

03-03

TG Therapeutics (TGTX) stock skyrocketed Monday after the biotech company handily beat Wall Street's fourth-quarter sales expectations and issued a bullish outlook for 2025.

Strategy" vid-repeat="1" vid-top="" vid-url="https://content.jwplatform.com/manifests/082BXcOe.m3u8" vid-width="100"> ↑ X NOW PLAYING How To Buy Stocks: Profit From Earnings Reports Using This Option Strategy

The company is well known for its multiple sclerosis treatment, Briumvi. During the fourth quarter and 2024, Briumvi brought in a respective $103.6 million and $310 million in sales. Sales soared roughly 250% year over year, TG said in a news release.

Both measures easily topped expectations. Analysts polled by FactSet called for $99.5 million in fourth-quarter sales and $305.9 million for the year.

For the current year, TG expects Briumvi to generate $540 million in sales, ahead of forecasts for $534.4 million.

TG Therapeutics stock rocketed 16.9% to 35.18. Shares bounded off their 50-day moving average and are closing in on a buy point at 36.84 out of a consolidation, according to MarketSurge. Shares also just landed on IBD's Leaderboard.

More to follow.

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up

The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists

Follow Premarket And After-The-Open Action With IBD Experts

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2516630481"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2516630481\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2516630481?lang=zh_CN&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/08/Stock-TGTherapeutics-01-shutt-640x360.jpg","is_english":true,"pubTime":"2025-03-03 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2516630481","market":"sg","top_or_hot":-1,"title":"TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide","media":"Blockhead","content":"<html><body><div>\n<p><strong>TG <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a></strong> (TGTX) stock skyrocketed Monday after the biotech company handily beat Wall Street's fourth-quarter sales expectations and issued a bullish outlook for 2025.</p>\n<span>\n<span>\n<span jw-video-key=\"082BXcOe\" vid-authors=\"RACHEL FOX\" vid-cat=\"Investor's Corner\" vid-date=\"11/30/2023\" vid-date-tmsp=\"1701349213\" vid-dom-id=\"8805438-67c5cb3b32d89\" vid-id=\"8805438\" vid-image=\"https://www.investors.com/wp-content/uploads/2023/11/IC_OptionsStrat-640x360.jpg\" vid-name=\"How To Buy Stocks: Profit From Earnings Reports Using This Option <a href=\"https://laohu8.com/S/MSTR\">Strategy</a>\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/082BXcOe.m3u8\" vid-width=\"100\">\n<span>↑</span>\n<span>X</span>\n<span>\n<span>NOW PLAYING</span>\n<span>How To Buy Stocks: Profit From Earnings Reports Using This Option Strategy</span>\n</span>\n</span>\n</span>\n</span>\n<p>The company is well known for its multiple sclerosis treatment, Briumvi. During the fourth quarter and 2024, Briumvi brought in a respective $103.6 million and $310 million in sales. Sales soared roughly 250% year over year, TG said in a news release.</p>\n<p>Both measures easily topped expectations. Analysts polled by FactSet called for $99.5 million in fourth-quarter sales and $305.9 million for the year.</p>\n<p>For the current year, TG expects Briumvi to generate $540 million in sales, ahead of forecasts for $534.4 million.</p>\n<p>TG Therapeutics stock rocketed 16.9% to 35.18. Shares bounded off their 50-day moving average and are closing in on a buy point at 36.84 out of a consolidation, according to MarketSurge. Shares also just landed on IBD's Leaderboard.</p>\n<p>More to follow.</p>\n<p><em>Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.</em></p>\n<p><strong>YOU MAY ALSO LIKE:</strong></p>\n<p>Behind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up</p>\n<p>The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks</p>\n<p>How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks</p>\n<p>Looking For The Next Apple Or Amazon? Start With These S&amp;P 500-Beating Lists</p>\n<p>Follow Premarket And After-The-Open Action With IBD Experts</p>\n</div></body></html>","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTG Therapeutics, A New Leaderboard Stock, Skyrockets 17% On Sales Beat, Bullish Guide\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-03 23:28 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>TG Therapeutics (TGTX) stock skyrocketed Monday after the biotech company handily beat Wall Street's fourth-quarter sales expectations and issued a bullish outlook for 2025.\n\n\nStrategy\" vid-repeat=\"1\"...</p>\n\n<a href=\"https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TGTX","symbol_name":"TG Therapeutics Inc.","start_time":0,"source_url":"https://www.investors.com/news/technology/tg-therapeutics-stock-tg-therapeutics-briumvi-sales-q4-2024/","article_id":"2516630481","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/08/Stock-TGTherapeutics-01-shutt-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2516630481","pubTimestamp":1741015689,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"TG Therapeutics stock skyrocketed Monday after easily beating fourth-quarter sales expectations and issuing a bullish outlook for 2025.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"TGTX":"TG Therapeutics Inc.","TG":"特里迪加"},"translate_title":"新排行榜股票TG Therapeutics因销售增长而飙升17%，看涨指南","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TG":1,"TGTX":1},"content_text":"TG Therapeutics (TGTX) stock skyrocketed Monday after the biotech company handily beat Wall Street's fourth-quarter sales expectations and issued a bullish outlook for 2025.\n\n\nStrategy\" vid-repeat=\"1\" vid-top=\"\" vid-url=\"https://content.jwplatform.com/manifests/082BXcOe.m3u8\" vid-width=\"100\">\n↑\nX\n\nNOW PLAYING\nHow To Buy Stocks: Profit From Earnings Reports Using This Option Strategy\n\n\n\n\nThe company is well known for its multiple sclerosis treatment, Briumvi. During the fourth quarter and 2024, Briumvi brought in a respective $103.6 million and $310 million in sales. Sales soared roughly 250% year over year, TG said in a news release.\nBoth measures easily topped expectations. Analysts polled by FactSet called for $99.5 million in fourth-quarter sales and $305.9 million for the year.\nFor the current year, TG expects Briumvi to generate $540 million in sales, ahead of forecasts for $534.4 million.\nTG Therapeutics stock rocketed 16.9% to 35.18. Shares bounded off their 50-day moving average and are closing in on a buy point at 36.84 out of a consolidation, according to MarketSurge. Shares also just landed on IBD's Leaderboard.\nMore to follow.\nFollow Allison Gatlin on X/Twitter at @AGatlin_IBD.\nYOU MAY ALSO LIKE:\nBehind Hims Stock's Roller-Coaster Ride As Weight-Loss Drugs Battle Heats Up\nThe Cream Of The Crop: 5 Biotechs That Outrank Most Stocks\nHow To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks\nLooking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists\nFollow Premarket And After-The-Open Action With IBD Experts","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}